Evaluation of Gadobutrol, a Macrocyclic, Nonionic Gadolinium Chelate in a Brain Glioma Model: Comparison With Gadoterate Meglumine and Gadopentetate Dimeglumine at 1.5 T, Combined with an Assessment of Field Strength Dependence, Specifically 1.5 Versus 3 T
Evaluation of Gadobutrol, a Macrocyclic, Nonionic Gadolinium Chelate in a Brain Glioma Model: Comparison With Gadoterate Meglumine and Gadopentetate Dimeglumine at 1.5 T, Combined with an Assessment of Field Strength Dependence, Specifically 1.5 Versus 3 T
复制标题
DOI：
10.1002/jmri.22089
复制
发表时间：
2010-03-01
影响因子：
4.4
通讯作者：
Michaely, Henrik J.
中科院分区：
文献类型：
--
作者：
Attenberger, Ulrike I.;Runge, Val M.;Michaely, Henrik J.
目的：在大鼠脑胶质瘤模型中，评价目前在美国临床试验中的非离子大环螯合物加多布曲尔(Gadovist)在1.5T下的肿瘤内增强作用，并与离子大环螯合物进行比较。Gadoterate葡胺(Dotarem)和离子线形螯合物Gadentetate Diglumine(Magnevist)，并比较1.5和3T时Gadobutrol对肿瘤的增强程度。材料和方法：24只大鼠分为3组，每组8只。第1组动物注射加多布曲尔和加多喷妥钠葡胺，第2组动物注射加多布曲尔和加多特罗葡胺。注射按随机顺序进行，间隔24小时。每次注射造影剂后立即行磁共振成像(MRI)检查。第3组动物使用相同的方案注射加多布特洛尔，但扫描温度分别为1.5和3T。在所有检查中，T1加权图像在平扫、增强后1分钟和此后连续4次连续2分钟间隔获得。结果：在造影剂注射后的各个时间点，组1和组2的肿瘤信噪比(SNR)和对比噪声比(CNR)均高于其他两种造影剂。与加多巴妥钠相比，加多布特洛尔对肿瘤CNR的改善在12%~40%之间，且在7min时差异有统计学意义。与加多特罗葡甲胺相比，加多布特洛尔对肿瘤CNR的改善在15%到27%之间，这取决于时间，在5分钟和9分钟时差异有统计学意义。在第3组中，随着磁场强度从1.5T增加到3T，在所有获得性时间点，肿瘤信噪比和CNR的改善都具有统计学意义(P<；0.002)。在1.5T时，CNR平均值在10.4+/-2.9到24.6+/-5.0之间；在3T时，CNR平均值在20.5+/-5.9到47.8+/-15.7之间，这取决于造影后的时间点。结论：在1.5T时，注射加多布曲尔的所有测量时间点的肿瘤强化程度均高于加多喷妥钠和加多特罗葡胺，而在3T时，加多布曲尔对肿瘤的增强效果显著。
Purpose: To evaluate in a rat brain glioma model intraindividual tumor enhancement at 1.5 T using gadobutrol (Gadovist), a nonionic, macrocyclic chelate currently in clinical trials in the United States, in comparison with both an ionic macrocyclic chelate. gadoterate meglumine (Dotarem), and an ionic linear chelate, gadopentetate dimeglumine (Magnevist), and to compare the degree of tumor enhancement with gadobutrol at 1.5 and 3 T.Materials and Methods: A total of 24 rats, divided into three groups with n = 8 animals per group, were evaluated. Animals in group 1 received injections of gadobutrol and gadopentetate dimeglumine, whereas those in group 2 received gadobutrol and gadoterate meglumine. Injections were performed in random order and separated by 24 hours. Magnetic resonance imaging (MRI) examinations were performed immediately following each contrast injection with a 1.5 T MR system. Animals in group 3 received gadobutrol injections using the same protocol but with scans performed at 1.5 and 3 T. In all examinations, T1-weighted images were acquired precontrast, 1 minute postcontrast, and at 4 consecutive 2-minute intervals thereafter. A contrast dose of 0.1 mmol/kg was used in all instances.Results: In groups 1 and 2, tumor signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were higher for gadobutrol compared to both other agents at each time-point postcontrast injection. The improvement in tumor CNR with gadobutrol, depending on time, was between 12% and 40% versus gadopentetate dimeglumine, with the difference achieving statistical significance at 7 minutes. The improvement in tumor CNR with gadobutrol, depending on time, was between 15% and 27% versus gadoterate meglumine, with the difference statistically significant at 5 and 9 minutes. In group 3 the improvement in tumor SNR and CNR seen with the increase in field strength from 1.5 to 3 T for gadobutrol was statistically significant at all acquired timepoints (P < 0.002). CNR mean values ranged from 10.4 +/- 2.9 to 24.6 +/- 5.0 at 1.5 T and from 20.5 +/- 5.9 to 47.8 +/- 15.7 at 3 T depending on the timepoint postcontrast.Conclusion: Consistently greater tumor enhancement was noted at all measured timepoints following contrast injection with gadobutrol compared to both gadopentetate dimeglumine and gadoterate meglumine at 1.5 T. A substantial further improvement in tumor enhancement was noted using gadobutrol at 3 T.